無料プレビュー

Evolus, Inc. (EOLS) · NASDAQ Global Market

プロフィール

Evolus, Inc. is a global performance beauty company that develops and commercializes injectable products for the medical aesthetics market. The company's primary offerings are Jeuveau®, a proprietary botulinum toxin type A formulation for frown lines, and Evolysse™, a collection of injectable hyaluronic acid gels for wrinkles, folds, and facial volume. Products are sold directly to licensed aesthetic practitioners in a cash-pay model in the United States, Canada, European markets, Australia, and other territories, with manufacturing outsourced to third-party suppliers.

主要指標

株価: $7.80 (+0.78%)
時価総額: 5億ドル
PER（今期予想）: -164.2
PBR: -16.6
配当利回り: —
52週レンジ: $3.86 – $9.31
業種: Healthcare / Drug Manufacturers - Specialty & Generic
上場: NASDAQ Global Market
構成銘柄: —

比較会社: TAK Takeda Pharmaceutical Company Limited、TEVA Teva Pharmaceutical Industries Limited、HLN Haleon plc、ZTS Zoetis Inc.、VTRS Viatris Inc.、ITCI Intra-Cellular Therapies, Inc.、CTLT Catalent, Inc.、ELAN Elanco Animal Health Incorporated

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

次回決算: 2026-11-04 · 更新: 2026-10-09